Bristol's Focused BioPharma Strategy Starts To Pay Off
While many of the world's leading drug companies have relied on mega-mergers and diversified portfolios to drive growth over the last five years, Bristol-Myers Squibb Co. has taken a different tact, jettisoning non-core businesses, slashing overhead and jobs, and announcing a plan to focus its portfolio solely on biopharma.
You may also be interested in...
TOKYO - Bristol-Myers Squibb Co. expects to stop a five-year skid in Japan sales by the end of FY2011, and CEO Lamberto Andreotti said the company will utilize its large cash reserves for new business development opportunities in an effort to become a top 20 company in Japan
Ranked 14th in pharma sales globally, the company isn't even among the top 20 pharmacos in Japan--but it plans on a change in portfolio mix and an emphasis on business development activities to change that profile.
BMS Adds To String Of Pearls: $470 Mil. Deal With French Biotech Brings Innate Immunity Approach Into Its R&D Pipeline
BMS deal with Innate Pharma strengthens the U.S. company's focus on cancer immunotherapy, and adds fillip to biotech companies in France.